{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:09:23Z","timestamp":1789578563122,"version":"build-2803163510"},"reference-count":186,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Total-body irradiation (TBI) based conditioning prior to allogeneic hematopoietic stem cell transplantation (HSCT) is generally regarded as the gold-standard for children &amp;gt;4 years of age with acute lymphoblastic leukaemia (ALL). Retrospective studies in the 1990's suggested better survival with irradiation, confirmed in a small randomised, prospective study in the early 2000's. Most recently, this was reconfirmed by the early results of the large, randomised, international, phase III FORUM study published in 2020. But we know survivors will suffer a multitude of long-term sequelae after TBI, including second malignancies, neurocognitive, endocrine and cardiometabolic effects. The drive to avoid TBI directs us to continue optimising irradiation-free, myeloablative conditioning. In chemotherapy-based conditioning, the dominant myeloablative effect is provided by the alkylating agents, most commonly busulfan or treosulfan. Busulfan with cyclophosphamide is a long-established alternative to TBI-based conditioning in ALL patients. Substituting fludarabine for cyclophosphamide reduces toxicity, but may not be as effective, prompting the addition of a third agent, such as thiotepa, melphalan, and now clofarabine. For busulfan, it's wide pharmacokinetic (PK) variability and narrow therapeutic window is well-known, with widespread use of therapeutic drug monitoring (TDM) to individualise dosing and control the cumulative busulfan exposure. The development of first-dose selection algorithms has helped achieve early, accurate busulfan levels within the targeted therapeutic window. In the future, predictive genetic variants, associated with differing busulfan exposures and toxicities, could be employed to further tailor individualised busulfan-based conditioning for ALL patients. Treosulfan-based conditioning leads to comparable outcomes to busulfan-based conditioning in paediatric ALL, without the need for TDM to date. Future PK evaluation and modelling may optimise therapy and improve outcome. More recently, the addition of clofarabine to busulfan\/fludarabine has shown encouraging results when compared to TBI-based regimens. The combination shows activity in ALL as well as AML and deserves further evaluation. Like busulfan, optimization of chemotherapy conditioning may be enhanced by understanding not just the PK of clofarabine, fludarabine, treosulfan and other agents, but also the pharmacodynamics and pharmacogenetics, ideally in the context of a single disease such as ALL.<\/jats:p>","DOI":"10.3389\/fped.2021.775485","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T14:40:11Z","timestamp":1639147211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia"],"prefix":"10.3389","volume":"9","author":[{"given":"Khalil","family":"Ben Hassine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Powys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Svec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslava","family":"Pozdechova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Versluys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/bmt.2010.280","article-title":"TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions","volume":"46","author":"Hill-Kayser","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"B2","first-page":"591","article-title":"Total-body irradiation in preparation for marrow engraftment","volume":"8","author":"Thomas","year":"1976","journal-title":"Transplant Proc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.pcl.2009.11.008","article-title":"The burden of cure: long-term side effects following hematopoietic stem cell transplantation (HSCT) in children","volume":"57","author":"Baker","year":"2010","journal-title":"Pediatr Clin North Am."},{"key":"B4","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1056\/NEJM197504172921605","article-title":"Bone-marrow transplantation (first of two parts)","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood.V49.4.511.511","article-title":"One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation","volume":"49","author":"Thomas","year":"1977","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1365-2141.1999.01337.x","article-title":"A history of haemopoietic cell transplantation","volume":"105","author":"Thomas","year":"1999","journal-title":"Br J Haematol."},{"key":"B7","first-page":"389","article-title":"Marrow transplantation in the treatment of acute childhood leukemia. Historical development and current approaches","volume":"3","author":"Johnson","year":"1981","journal-title":"Am J Pediatr Hematol Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3109\/10428199309047886","article-title":"Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia\u2013a review","volume":"11","author":"Santos","year":"1993","journal-title":"Leuk Lymphoma."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":"Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide","volume":"309","author":"Santos","year":"1983","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","article-title":"Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen","volume":"70","author":"Tutschka","year":"1987","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood.V79.10.2578.bloodjournal79102578","article-title":"Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse","volume":"79","author":"Blaise","year":"1992","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1182\/blood.V85.8.2263.bloodjournal8582263","article-title":"Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM)","volume":"85","author":"Devergie","year":"1995","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/blood.V83.9.2723.2723","article-title":"A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group","volume":"83","author":"Ringden","year":"1994","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1182\/blood.V84.6.2036.2036","article-title":"Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide","volume":"84","author":"Clift","year":"1994","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/sj.bmt.1701334","article-title":"Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan\/cyclophosphamide vs total body irradiation: a meta-analysis","volume":"22","author":"Hartman","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1182\/blood.V97.11.3669","article-title":"Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission","volume":"97","author":"Blaise","year":"2001","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood.V93.7.2196","article-title":"Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with Busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia","volume":"93","author":"Ringd\u00e9n","year":"1999","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1182\/blood.V98.13.3569","article-title":"Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies","volume":"98","author":"Socie","year":"2001","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2000.18.2.340","article-title":"Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia","volume":"18","author":"Davies","year":"2000","journal-title":"J Clin Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/sj.bmt.1704198","article-title":"Randomized trial of busulfan vs. total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study","volume":"32","author":"Bunin","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1182\/blood-2005-12-4942","article-title":"Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research","volume":"107","author":"Eapen","year":"2006","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1182\/blood-2007-07-099283","article-title":"Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party","volume":"111","author":"Friedman","year":"2008","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/blood-2008-08-173005","article-title":"Thyroid function following hematopoietic cell transplantation in children: 30 years' experience","volume":"113","author":"Sanders","year":"2009","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","article-title":"Solid cancers after allogeneic hematopoietic cell transplantation","volume":"113","author":"Rizzo","year":"2009","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1038\/sj.bmt.1702351","article-title":"Allogeneic stem cell transplantation (BMT) for AML and MDS following iv busulfan and cyclophosphamide (iv BuCy)","volume":"25","author":"Andersson","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"B26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","article-title":"Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant."},{"key":"B27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bbmt.2007.09.015","article-title":"Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation","volume":"14","author":"Bartelink","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1016\/j.ejca.2012.05.020","article-title":"Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1\/SIOPEN trial","volume":"48","author":"Veal","year":"2012","journal-title":"Eur J Cancer."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.bbmt.2013.09.012","article-title":"Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia","volume":"19","author":"Kato","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/sj.leu.2402552","article-title":"Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL","volume":"16","author":"Bader","year":"2002","journal-title":"Leukemia."},{"key":"B31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.13142","article-title":"Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia","volume":"168","author":"Sutton","year":"2015","journal-title":"Br J Haematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2141.2006.06330.x","article-title":"Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies","volume":"135","author":"Chen","year":"2006","journal-title":"Br J Haematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/bjh.12810","article-title":"Transplantation of CD3\/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia","volume":"165","author":"Lang","year":"2014","journal-title":"Br J Haematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood all: a multinational, randomized, non-inferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing busulfan-based conditioning: considerations from the american society for blood and marrow transplantation practice guidelines committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.bbmt.2008.11.022","article-title":"Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation","volume":"15","author":"Bartelink","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"key":"B38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/FTD.0b013e3182a04fc7","article-title":"Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation","volume":"36","author":"Ansari","year":"2014","journal-title":"Ther Drug Monit."},{"key":"B39","unstructured":"GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study9085267\n            AnsariM\n            CurtisPH-D\n            UppugunduriCRS\n            RezguiMA\n            NavaT\n            MlakarV\n          10.18632\/oncotarget.2031029207608Oncotarget.82017"},{"key":"B40","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/sj.bmt.1702590","article-title":"Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia","volume":"26","author":"Baker","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/S2352-3026(17)30018-2","article-title":"Busulfan after HSCT in children and young adults \u2013 authors' reply","volume":"4","author":"Bartelink","year":"2017","journal-title":"Lancet Haematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0193862","DOI":"10.1371\/journal.pone.0193862","article-title":"Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children","volume":"13","author":"Benadiba","year":"2018","journal-title":"PLoS ONE."},{"key":"B43","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/sj.bmt.1702371","article-title":"An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease","volume":"25","author":"Bolinger","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.bmt.1703264","article-title":"Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation","volume":"28","author":"Bolinger","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/sj.bmt.1703047","article-title":"Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation","volume":"27","author":"Copelan","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"B46","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/hon.2789","article-title":"Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5,000 \u03bcMol min. A historically controlled clinical trial","volume":"38","author":"Esteves","year":"2020","journal-title":"Hematol Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00694339","article-title":"Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation","volume":"25","author":"Grochow","year":"1989","journal-title":"Cancer Chemother Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/pbc.24827","article-title":"Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients","volume":"61","author":"Kerl","year":"2014","journal-title":"Pediatr Blood Cancer."},{"key":"B49","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/sj.bmt.1700994","article-title":"High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients","volume":"20","author":"Ljungman","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"B50","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41409-018-0281-7","article-title":"Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children","volume":"54","author":"Philippe","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"B51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.bmt.1704707","article-title":"Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity","volume":"35","author":"Zwaveling","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"B52","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/sj.bmt.1703612","article-title":"Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"30","author":"McCune","year":"2002","journal-title":"Bone Marrow Transplant."},{"key":"B53","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/bmt.2015.218","article-title":"Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children","volume":"51","author":"Philippe","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B54","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bbmt.2006.10.026","article-title":"Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Schechter","year":"2007","journal-title":"Biol Blood Marrow Transplant."},{"key":"B55","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.bmt.1704275","article-title":"In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa)","volume":"32","author":"Bouligand","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"B56","unstructured":"2018"},{"key":"B57","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.bmt.1704446","article-title":"Busulfan in pediatrics: a novel dosing to improve safety\/efficacy for hematopoietic progenitor cell transplantation recipients","volume":"33","author":"Nguyen","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"B58","first-page":"18","article-title":"Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens","volume":"20","author":"Grochow","year":"1993","journal-title":"Semin Oncol."},{"key":"B59","first-page":"225","article-title":"Association of busulfan area under the curve with veno-occlusive disease following BMT","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"B60","first-page":"31","article-title":"Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"B61","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-1-4615-1173-1_16","article-title":"Pharmacological considerations of primary alkylators","volume":"112","author":"McCune","year":"2002","journal-title":"Cancer Treat Res."},{"key":"B62","first-page":"31","article-title":"Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"B63","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/0091270006295789","article-title":"Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients","volume":"47","author":"Booth","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12887-020-02028-6","article-title":"Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis","volume":"20","author":"Feng","year":"2020","journal-title":"BMC Pediatr."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.bbmt.2019.05.021","article-title":"Harmonization of busulfan plasma exposure unit (BPEU): a community-initiated consensus statement","volume":"25","author":"McCune","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/S2352-3026(16)30189-2","article-title":"Busulfan after HSCT in children and young adults","volume":"4","author":"Paci","year":"2017","journal-title":"Lancet Haematol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.bbmt.2013.08.014","article-title":"Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation","volume":"19","author":"Savic","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B68","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/sj.bmt.1704560","article-title":"Busulphan given as four single daily doses of 150 mg\/m2 is safe and effective in children of all ages","volume":"34","author":"Shaw","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1097\/01.cad.0000231482.15277.48","article-title":"Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"17","author":"Zwaveling","year":"2006","journal-title":"Anticancer Drugs."},{"key":"B70","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/MPH.0b013e3182431e1b","article-title":"Once-daily intravenous busulfan for 47 pediatric patients undergoing autologous hematopoietic stem cell transplantation: a single center study","volume":"34","author":"Gonz\u00e1lez-Vicent","year":"2012","journal-title":"J Pediatr Hematol Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.bbmt.2011.11.025","article-title":"Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling","volume":"18","author":"Lee","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"key":"B72","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bbmt.2014.09.013","article-title":"Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B73","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/bmt.2013.220","article-title":"Optimization of health-care organization and perceived improvement of patient comfort by switching from intra-venous BU four-times-daily infusions to a once-daily administration scheme in adult hematopoietic stem cell recipients","volume":"49","author":"Xhaard","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"B74","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bbmt.2019.09.008","article-title":"Costs and outcomes with once-daily versus every-6-hour intravenous busulfan in allogeneic hematopoietic cell transplantation","volume":"26","author":"Singhal","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"key":"B75","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00280-021-04288-0","article-title":"Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation","volume":"88","author":"Lawson","year":"2021","journal-title":"Cancer Chemother Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Azab","year":"2009","journal-title":"Blood."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/s00277-018-3447-x","article-title":"The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients","volume":"97","author":"Willcox","year":"2018","journal-title":"Ann Hematol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.bbmt.2005.12.028","article-title":"Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation","volume":"12","author":"Kletzel","year":"2006","journal-title":"Biol Blood Marrow Transplant."},{"key":"B79","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/jcph.1049","article-title":"Test dose pharmacokinetics in pediatric patients receiving once-daily IV busulfan conditioning for hematopoietic stem cell transplant: a reliable approach?","volume":"58","author":"Brooks","year":"2018","journal-title":"J Clin Pharmacol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2165\/11598180-000000000-00000","article-title":"Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: toward individualized dosing","volume":"51","author":"Bartelink","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"B81","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/FTD.0b013e31826051bb","article-title":"Predictive performance of a busulfan pharmacokinetic model in children and young adults","volume":"34","author":"Bartelink","year":"2012","journal-title":"Ther Drug Monit"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/psp4.12683","article-title":"Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: results from a multicenter population pharmacokinetic study","volume":"10","author":"Ben Hassine","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.2217\/pgs.15.98","article-title":"Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Choi","year":"2015","journal-title":"Pharmacogenomics."},{"key":"B84","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00228-014-1692-z","article-title":"Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM\u00ae model to optimize dosing","volume":"70","author":"Diestelhorst","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/jcph.1120","article-title":"Population pharmacokinetic analysis of busulfan in Japanese pediatric and adult HCT patients","volume":"58","author":"Kawazoe","year":"2018","journal-title":"J Clin Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1158\/1078-0432.CCR-13-1960","article-title":"Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization","volume":"20","author":"McCune","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/bcp.14256","article-title":"A semi-mechanistic model based on glutathione depletion to describe intra-individual reduction in busulfan clearance","volume":"86","author":"Langenhorst","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FTD.0000000000000131","article-title":"Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use","volume":"37","author":"Long-Boyle","year":"2015","journal-title":"Ther Drug Monit."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/bcp.13566","article-title":"Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation: GSTA1-based busulfan population pharmacokinetic model in children","volume":"84","author":"Nava","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/FTD.0000000000000276","article-title":"Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software","volume":"38","author":"Neely","year":"2016","journal-title":"Ther Drug Monit."},{"key":"B91","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40262-016-0448-6","article-title":"Nonparametric method to optimize initial drug dosing and attainment of a target exposure interval: concepts and application to busulfan in pediatrics","volume":"56","author":"Philippe","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e28603","DOI":"10.1002\/pbc.28603","article-title":"New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning","volume":"67","author":"Poinsignon","year":"2020","journal-title":"Pediatr Blood Cancer."},{"key":"B93","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/ajh.24734","article-title":"Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram","volume":"92","author":"Rhee","year":"2017","journal-title":"Am J Hematol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fphar.2020.00888","article-title":"Assessment of a model-informed precision dosing platform use in routine clinical care for personalized busulfan therapy in the pediatric hematopoietic cell transplantation (HCT) population","volume":"11","author":"Shukla","year":"2020","journal-title":"Front Pharmacol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.1158\/1078-0432.CCR-11-0074","article-title":"Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children","volume":"17","author":"Trame","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/1440-1681.12735","article-title":"Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation","volume":"44","author":"Wu","year":"2017","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/PGPM.S289834","article-title":"Optimization of busulfan dosing regimen in pediatric patients using a population pharmacokinetic model incorporating GST mutations","volume":"14","author":"Yuan","year":"2021","journal-title":"Pharmgenomics Pers Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/FTD.0b013e3181817428","article-title":"Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients","volume":"30","author":"Zwaveling","year":"2008","journal-title":"Ther Drug Monit."},{"key":"B99","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/FTD.0b013e31829dc940","article-title":"Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved?","volume":"36","author":"Buffery","year":"2014","journal-title":"Ther Drug Monit."},{"key":"B100","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/pbc.22227","article-title":"Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation","volume":"54","author":"Wall","year":"2010","journal-title":"Pediatr Blood Cancer."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.bbmt.2015.05.006","article-title":"Performance of busulfan dosing guidelines for pediatric hematopoietic stem cell transplant conditioning","volume":"21","author":"Zao","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B102","unstructured":"GSTA1 genetic variants and conditioning regimen: missing key factors in dosing guidelines of busulfan in pediatric hematopoietic stem cell transplantation191824\n            NavaT\n            RezguiMA\n            UppugunduriCRS\n            CurtisPH-D\n            Th\u00e9oretY\n            DuvalM\n          10.1016\/j.bbmt.2017.07.02228807770Biol Blood Marrow Transplant.232017"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e13696","DOI":"10.1111\/petr.13696","article-title":"Pharmacokinetic analysis for model-supported therapeutic drug monitoring of busulfan in Japanese pediatric hematopoietic stem cell transplantation recipients","volume":"24","author":"Kishimoto","year":"2020","journal-title":"Pediatr Transplant."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.3109\/10428194.2010.520773","article-title":"Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome\/veno-occlusive disease","volume":"51","author":"O'Donnell","year":"2010","journal-title":"Leuk Lymphoma."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1177\/0091270010382915","article-title":"Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients","volume":"51","author":"Abbasi","year":"2011","journal-title":"J Clin Pharmacol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/bmt.2009.143","article-title":"Influence of GST gene polymorphisms on busulfan pharmacokinetics in children","volume":"45","author":"Ansari","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"B107","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/bmt.2012.265","article-title":"Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients","volume":"48","author":"Ansari","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"B108","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/bmt.2015.321","article-title":"Influence of glutathione S -transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients","volume":"51","author":"Ansari","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B109","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3324\/haematol.2013.089888","article-title":"Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation","volume":"99","author":"Bonifazi","year":"2014","journal-title":"Haematologica."},{"key":"B110","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/FTD.0000000000000180","article-title":"Glutathione transferase gene variants influence busulfan pharmacokinetics and outcome after myeloablative conditioning","volume":"37","author":"Bremer","year":"2015","journal-title":"Ther Drug Monit."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/pbc.22739","article-title":"Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation","volume":"55","author":"Elhasid","year":"2010","journal-title":"Pediatr Blood Cancer."},{"key":"B112","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1182\/blood-2010-01-265405","article-title":"Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring","volume":"115","author":"Gaziev","year":"2010","journal-title":"Blood."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1177\/0091270008321940","article-title":"Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation","volume":"48","author":"Johnson","year":"2008","journal-title":"J Clin Pharmacol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.bbmt.2010.12.708","article-title":"Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation","volume":"17","author":"Kim","year":"2011","journal-title":"Biol Blood Marrow Transplant."},{"key":"B115","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/ped.13859","article-title":"Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children","volume":"61","author":"Nishikawa","year":"2019","journal-title":"Pediatr Int."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood-2003-11-3778","article-title":"Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation","volume":"104","author":"Srivastava","year":"2004","journal-title":"Blood."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2217\/pgs.13.159","article-title":"Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"14","author":"ten Brink","year":"2013","journal-title":"Pharmacogenomics"},{"key":"B118","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/tpj.2013.38","article-title":"The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"14","author":"Uppugunduri","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"B119","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/bmt.2015.14","article-title":"Once-daily iv BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients","volume":"50","author":"Yin","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"B120","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/rcm.7730","article-title":"Detection of busulfan adducts on proteins","volume":"30","author":"Acosta-Martin","year":"2016","journal-title":"Rapid Commun Mass Spectrom."},{"key":"B121","first-page":"1015","article-title":"Busulfan conjugation by glutathione S-transferases alpha, mu, and pi","volume":"24","author":"Czerwinski","year":"1996","journal-title":"Drug Metab Dispos."},{"key":"B122","first-page":"52","article-title":"Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro","volume":"26","author":"Gibbs","year":"1998","journal-title":"Drug Metab Dispos."},{"key":"B123","first-page":"3678","article-title":"Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases","volume":"56","author":"Gibbs","year":"1996","journal-title":"Cancer Res."},{"key":"B124","unstructured":"The analysis of GSTA1 promoter genetic and functional diversity of human populations5038\n            MlakarV\n            CurtisPH-D\n            ArmengolM\n            YthierV\n            DupanloupI\n            HassineKB\n          10.1038\/s41598-021-83996-233658540Sci Rep.112021"},{"key":"B125","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/1389200215666140202214012","article-title":"Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children","volume":"15","author":"Huezo-Diaz","year":"2014","journal-title":"Curr Drug Metab."},{"key":"B126","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/jpm11050347","article-title":"Genetic predictors for sinusoidal obstruction syndrome\u2014a systematic review","volume":"11","author":"Waespe","year":"2021","journal-title":"J Pers Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/tpj.2016.65","article-title":"Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation","volume":"18","author":"Huezo-Diaz Curtis","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"B128","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41397-021-00251-7","article-title":"Association study of candidate DNA-repair gene variants and acute graft vs. host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation","volume":"2021","author":"Uppugunduri","year":"2021","journal-title":"Pharmacogenomics J."},{"key":"B129","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41409-021-01386-8","article-title":"Genetic susceptibility to acute graft versus host disease in pediatric patients undergoing HSCT","volume":"2021","author":"Ansari","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"B130","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fimmu.2018.00109","article-title":"Donor genotype in the interleukin-7 receptor alpha-chain predicts risk of graft-versus-host disease and cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Kielsen","year":"2018","journal-title":"Front Immunol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/TP.0b013e3182708e7c","article-title":"Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease","volume":"94","author":"Kim","year":"2012","journal-title":"Transplantation."},{"key":"B132","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/sj.bjc.6690043","article-title":"DNA alkylation and interstrand cross-linking by treosulfan","volume":"79","author":"Hartley","year":"1999","journal-title":"Br J Cancer."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1021\/acs.molpharmaceut.9b00251","article-title":"Kinetics of in vitro guanine- N7-alkylation in calf thymus DNA by (2 S,3 S)-1,2-epoxybutane-3,4-diol 4-methanesulfonate and (2 S,3 S)-1,2:3,4-diepoxybutane: revision of the mechanism of DNA cross-linking by the prodrug treosulfan","volume":"16","author":"Romanski","year":"2019","journal-title":"Mol Pharm."},{"key":"B134","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.1365-2141.2008.07385.x","article-title":"Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major","volume":"143","author":"Bernardo","year":"2008","journal-title":"Br J Haematol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1365-2141.2008.07399.x","article-title":"Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation","volume":"143","author":"Cutting","year":"2008","journal-title":"Br J Haematol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1365-2141.2008.07064.x","article-title":"Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities","volume":"142","author":"Greystoke","year":"2008","journal-title":"Br J Haematol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.bbmt.2014.08.020","article-title":"Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial","volume":"20","author":"Burroughs","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"key":"B138","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2016-03-704015","article-title":"Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience","volume":"128","author":"Morillo-Gutierrez","year":"2016","journal-title":"Blood."},{"key":"B139","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbmt.2017.11.009","article-title":"Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience","volume":"24","author":"Slatter","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B140","doi-asserted-by":"publisher","first-page":"e61637","DOI":"10.1371\/journal.pone.0061637","article-title":"Improved clinical outcomes of high risk beta thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts","volume":"8","author":"Mathews","year":"2013","journal-title":"PLoS ONE."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/j.bbmt.2019.05.005","article-title":"Gonadal function after busulfan compared with treosulfan in children and adolescents undergoing allogeneic hematopoietic stem cell transplant","volume":"25","author":"Faraci","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/bmt.2010.343","article-title":"Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party","volume":"46","author":"Wachowiak","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"B143","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/bmt.2012.188","article-title":"Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience","volume":"48","author":"Beier","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"B144","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/pbc.25764","article-title":"European society for blood and marrow transplantation analysis of treosulfan conditioning before hematopoietic stem cell transplantation in children and adolescents with hematological malignancies","volume":"63","author":"Boztug","year":"2016","journal-title":"Pediatr Blood Cancer."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41409-020-0869-6","article-title":"Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies","volume":"55","author":"Kalwak","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.bbmt.2018.04.025","article-title":"Treosulfan, fludarabine, and low-dose total body irradiation for children and young adults with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation: prospective phase II trial of the pediatric blood and marrow transplant consortium","volume":"24","author":"Nemecek","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B147","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.bbmt.2017.12.776","article-title":"Intravenous busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the acute leukemia working party of European society for blood and marrow transplantation","volume":"24","author":"Shimoni","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B148","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1002\/cncr.30646","article-title":"Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"123","author":"Nagler","year":"2017","journal-title":"Cancer."},{"key":"B149","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bjh.14960","article-title":"High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study","volume":"179","author":"van der Stoep","year":"2017","journal-title":"Br J Haematol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/cpt.1715","article-title":"Proposed therapeutic range of treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: results from a prospective trial","volume":"108","author":"Chiesa","year":"2020","journal-title":"Clin Pharmacol Ther."},{"key":"B151","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/cpt.988","article-title":"Pharmacokinetics and pharmacodynamics of treosulfan in patients with thalassemia major undergoing allogeneic hematopoietic stem cell transplantation","volume":"104","author":"Mohanan","year":"2018","journal-title":"Clin Pharmacol Ther."},{"key":"B152","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1111\/bcp.13995","article-title":"Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation","volume":"85","author":"van der Stoep","year":"2019","journal-title":"Br J Clin Pharmacol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.drudis.2014.04.005","article-title":"Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics","volume":"19","author":"ten Brink","year":"2014","journal-title":"Drug Discov Today."},{"key":"B154","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00228-017-2344-x","article-title":"Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation","volume":"74","author":"Danielak","year":"2018","journal-title":"Eur J Clin Pharmacol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/00148581-200507040-00005","article-title":"Clofarabine: in pediatric patients with acute lymphoblastic leukemia","volume":"7","author":"Curran","year":"2005","journal-title":"Paediatr Drugs."},{"key":"B156","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood-2003-06-2122","article-title":"Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia","volume":"103","author":"Jeha","year":"2004","journal-title":"Blood."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1182\/blood-2011-08-374710","article-title":"Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"118","author":"Hijiya","year":"2011","journal-title":"Blood."},{"key":"B159","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1365-2141.2011.08752.x","article-title":"Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia","volume":"154","author":"O'Connor","year":"2011","journal-title":"Br J Haematol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2141.2009.07882.x","article-title":"Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory\/multiple relapsed acute lymphoblastic leukaemia","volume":"147","author":"Locatelli","year":"2009","journal-title":"Br J Haematol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","article-title":"Once daily iv busulfan and fludarabine (iv Bu-Flu) compares favorably with iv busulfan and cyclophosphamide (iv BuCy2) as pretransplant conditioning therapy in AML\/MDS","volume":"14","author":"Andersson","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"B162","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.bbmt.2010.09.022","article-title":"Clofarabine +\/- fludarabine with once daily iv busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS","volume":"17","author":"Andersson","year":"2011","journal-title":"Biol Blood Marrow Transplant."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.bbmt.2016.06.023","article-title":"Long-term outcomes after treatment with clofarabine +\/- fludarabine with once-daily intravenous busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and myelodysplastic syndrome","volume":"22","author":"Alatrash","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.bbmt.2012.06.010","article-title":"Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Kebriaei","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"key":"B165","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bbmt.2016.11.001","article-title":"Clofarabine plus busulfan is an effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: long-term study results","volume":"23","author":"Kebriaei","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/s41409-020-01201-w","article-title":"Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens","volume":"56","author":"Versluys","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"B167","doi-asserted-by":"publisher","first-page":"214","DOI":"10.12659\/AOT.889933","article-title":"The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children","volume":"19","author":"Tesfaye","year":"2014","journal-title":"Ann Transplant."},{"key":"B168","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/bmt.2015.238","article-title":"Busulfan fludarabine vs. busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis","volume":"51","author":"Ben-Barouch","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B169","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.bbmt.2013.11.027","article-title":"Fludarabine and exposure-targeted busulfan compares favorably with busulfan\/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity","volume":"20","author":"Bartelink","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1182\/bloodadvances.2018016956","article-title":"Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine","volume":"2","author":"Harris","year":"2018","journal-title":"Blood Advances."},{"key":"B171","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/jcph.1027","article-title":"Population pharmacokinetics of intravenous busulfan in Japanese pediatric patients with primary immunodeficiency diseases","volume":"58","author":"Ishiwata","year":"2018","journal-title":"J Clin Pharmacol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.bbmt.2011.06.013","article-title":"Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients","volume":"18","author":"Yeh","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"key":"B173","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/bmt.2010.53","article-title":"High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation","volume":"46","author":"Long-Boyle","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.bbmt.2017.06.021","article-title":"Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients","volume":"23","author":"Ivaturi","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B175","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41409-018-0260-z","article-title":"Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients","volume":"54","author":"Chung","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"B176","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1182\/bloodadvances.2018029421","article-title":"Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes","volume":"3","author":"Langenhorst","year":"2019","journal-title":"Blood Adv."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/ajh.25225","article-title":"Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia","volume":"93","author":"Saraceni","year":"2018","journal-title":"Am J Hematol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.18632\/oncotarget.23273","article-title":"Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission","volume":"9","author":"Saraceni","year":"2018","journal-title":"Oncotarget."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/bmt.2012.13","article-title":"Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen","volume":"47","author":"Sanz","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"B180","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-018-0655-8","article-title":"Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine","volume":"11","author":"Giannotti","year":"2018","journal-title":"J Hematol Oncol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/leu.2013.259","article-title":"Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT","volume":"28","author":"Ruggeri","year":"2014","journal-title":"Leukemia."},{"key":"B182","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1182\/blood-2012-08-453399","article-title":"Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies","volume":"121","author":"Di Bartolomeo","year":"2013","journal-title":"Blood."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1080\/10428194.2020.1788015","article-title":"Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus\/sirolimus as graft vs. host disease prophylaxis","volume":"61","author":"Fox","year":"2020","journal-title":"Leuk Lymphoma."},{"key":"B184","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1345\/aph.1L428","article-title":"Treatment of multiple myeloma in the targeted therapy era","volume":"43","author":"Saad","year":"2009","journal-title":"Ann Pharmacother."},{"key":"B185","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.bbmt.2008.02.016","article-title":"Myeloablative intravenous busulfan\/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients","volume":"14","author":"Horwitz","year":"2008","journal-title":"Biol Blood Marrow Transplantat."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.bbmt.2019.02.025","article-title":"Thiotepa, busulfan, and fludarabine conditioning regimen in T cell-replete HLA-haploidentical hematopoietic stem cell transplantation","volume":"25","author":"Dulery","year":"2019","journal-title":"Biol Blood Marrow Transplant."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.775485\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T14:40:24Z","timestamp":1639147224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.775485\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":186,"alternative-id":["10.3389\/fped.2021.775485"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.775485","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]},"article-number":"775485"}}